Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRGOTCMKTS:ICOTFNASDAQ:PMNNASDAQ:TXMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRGBullfrog AI$1.77-8.1%$1.71$1.23▼$4.84$16.62M0.71392,270 shs133,806 shsICOTFiCo Therapeutics$0.46+0.5%$0.37$0.80▼$1.82$4.14M2.034,760 shs62,844 shsPMNProMIS Neurosciences$0.51-2.9%$0.63$0.47▼$2.37$16.51M0.0275,530 shs37,472 shsTXMDTherapeuticsMD$1.46-3.9%$1.05$0.70▼$2.44$16.90M0.5155,847 shs23,142 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRGBullfrog AI+8.47%+12.61%-8.57%-40.74%-35.72%ICOTFiCo Therapeutics-5.60%-2.19%+1.13%-12.84%+33.82%PMNProMIS Neurosciences+3.79%-9.57%-7.08%-43.04%-74.00%TXMDTherapeuticsMD+2.70%+7.80%+53.57%+50.50%-26.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRGBullfrog AI1.1854 of 5 stars0.04.00.00.03.12.50.0ICOTFiCo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APMNProMIS Neurosciences1.9325 of 5 stars3.52.00.00.02.20.80.6TXMDTherapeuticsMD1.3735 of 5 stars0.05.00.00.02.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRGBullfrog AI 0.00N/AN/AN/AICOTFiCo Therapeutics 0.00N/AN/AN/APMNProMIS Neurosciences 3.00Buy$4.50791.09% UpsideTXMDTherapeuticsMD 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ICOTF, TXMD, BFRG, and PMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025PMNProMIS NeurosciencesMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$3.004/1/2025PMNProMIS NeurosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.002/26/2025PMNProMIS NeurosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRGBullfrog AI$60K276.96N/AN/A$0.43 per share4.10ICOTFiCo TherapeuticsN/AN/AN/AN/A($0.07) per shareN/APMNProMIS NeurosciencesN/AN/AN/AN/A$0.20 per shareN/ATXMDTherapeuticsMD$1.76M9.60N/AN/A$2.77 per share0.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRGBullfrog AI-$5.36M-$0.86N/A∞N/AN/A-141.39%-124.63%N/AICOTFiCo Therapeutics-$1.11M-$0.40N/A∞N/AN/AN/A-288.85%N/APMNProMIS Neurosciences-$13.21M-$0.03N/AN/AN/AN/A-636.20%-130.32%N/ATXMDTherapeuticsMD-$10.28MN/A0.00∞N/A-207.77%-14.08%-9.61%N/ALatest ICOTF, TXMD, BFRG, and PMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025BFRGBullfrog AIN/A-$0.21N/A-$0.21N/AN/A5/13/2025Q1 2025TXMDTherapeuticsMDN/A-$0.06N/A-$0.06N/A$0.39 million5/12/2025Q1 2025PMNProMIS Neurosciences-$0.14-$0.21-$0.07-$0.21N/AN/A3/31/2025Q4 2024PMNProMIS Neurosciences-$0.14-$0.02+$0.12-$0.02N/AN/A3/14/2025Q4 2024BFRGBullfrog AIN/A-$0.18N/A-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRGBullfrog AIN/AN/AN/AN/AN/AICOTFiCo TherapeuticsN/AN/AN/AN/AN/APMNProMIS NeurosciencesN/AN/AN/AN/AN/ATXMDTherapeuticsMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRGBullfrog AIN/A5.905.90ICOTFiCo TherapeuticsN/A0.720.72PMNProMIS NeurosciencesN/A9.309.30TXMDTherapeuticsMDN/A2.032.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRGBullfrog AI0.96%ICOTFiCo TherapeuticsN/APMNProMIS Neurosciences50.13%TXMDTherapeuticsMD30.74%Insider OwnershipCompanyInsider OwnershipBFRGBullfrog AI33.90%ICOTFiCo TherapeuticsN/APMNProMIS Neurosciences4.40%TXMDTherapeuticsMD2.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRGBullfrog AI49.42 million5.76 millionNot OptionableICOTFiCo TherapeuticsN/A9.05 millionN/ANot OptionablePMNProMIS Neurosciences532.69 million31.25 millionNot OptionableTXMDTherapeuticsMD42011.57 million11.27 millionOptionableICOTF, TXMD, BFRG, and PMN HeadlinesRecent News About These CompaniesTherapeuticsMD Announces First Quarter 2025 Financial ResultsMay 13 at 4:05 PM | businesswire.comTherapeuticsMD Inc. stock rises Monday, still underperforms marketMay 12 at 10:12 PM | marketwatch.comTherapeuticsMD Inc. stock outperforms competitors despite losses on the dayApril 8, 2025 | marketwatch.comTherapeuticsMD Announces Full Year 2024 Financial ResultsMarch 27, 2025 | businesswire.comTherapeuticsMD, Inc. (TXMD) Latest Press Releases & Corporate News - Yahoo FinanceMarch 26, 2025 | finance.yahoo.comTherapeuticsMD Inc’s Stock Drama: Could This Be a Game-Changer for TXMD Investors?January 7, 2025 | bovnews.comTherapeuticsMD Inc (TXMD) Stock: A Deeper Look at Its True PotentialJanuary 3, 2025 | bovnews.comTherapeuticsMD Inc. stock remains steady Friday, still outperforms marketDecember 27, 2024 | marketwatch.comTherapeuticsMD Inc. stock underperforms Friday when compared to competitors despite daily gainsNovember 23, 2024 | marketwatch.comTherapeuticsMD Shifts Focus with Lower Q3 LossesNovember 15, 2024 | markets.businessinsider.comTherapeuticsMD Reports Reduced Losses Amid Strategic ShiftNovember 15, 2024 | markets.businessinsider.comTherapeuticsMD Announces Third Quarter 2024 Financial ResultsNovember 13, 2024 | finance.yahoo.comTherapeuticsMD Inc. stock remains steady Monday, underperforms marketNovember 12, 2024 | marketwatch.comTherapeuticsMD (NASDAQ:TXMD) Stock, Option ChainNovember 6, 2024 | benzinga.comTherapeuticsMD Inc. stock remains steady Wednesday, underperforms marketNovember 6, 2024 | marketwatch.comTherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors despite daily gainsOctober 22, 2024 | marketwatch.comTherapeuticsMD Inc. stock remains steady Thursday, underperforms marketOctober 17, 2024 | marketwatch.comTherapeuticsMD Inc. stock remains steady Friday, underperforms marketOctober 11, 2024 | marketwatch.comTherapeuticsMD Inc. stock remains steady Thursday, still outperforms marketOctober 11, 2024 | marketwatch.comTherapeuticsMD Inc. stock underperforms Monday when compared to competitors despite daily gainsSeptember 30, 2024 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeICOTF, TXMD, BFRG, and PMN Company DescriptionsBullfrog AI NASDAQ:BFRG$1.76 -0.16 (-8.07%) As of 04:00 PM EasternBullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.iCo Therapeutics OTCMKTS:ICOTFSatellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.ProMIS Neurosciences NASDAQ:PMN$0.50 -0.02 (-2.88%) As of 03:47 PM EasternProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.TherapeuticsMD NASDAQ:TXMD$1.46 -0.06 (-3.95%) As of 04:00 PM EasternTherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
